Search bioRxiv⌕ Search

Biology subjects

Coleman, K. L.

Publications and source records attributed to Coleman, K. L..

2 recordsLinked to original sources

Borrelia burgdorferi bb0164 encodes a Na+/Ca2+ antiporter homolog with a novel role in Mn2+ homeostasis and infectivity

Borrelia burgdorferi, the Lyme disease causative agent, relies on trace metals for motility, growth, and virulence in the absence of metal transport homologues encoded in the genome. Previous studies characterized borrelial metal transporter (bmtA) as a manganese (Mn) transporter and speculated that it is the sole Mn transporter. An oxidative stress transposon library screen identified bb0164, annotated as a calcium/sodium antiporter, as having a putative metal binding domain. The transposon mutant lost the ability to internalize Mn suggesting B. burgdorferi is using a non-canonical protein for metal transport. In this study, a bb0164 deletion and complement were generated in B. burgdorferi 5A4-NP1 to evaluate for trace metal transport, virulence regulation, resistance to oxidative stress, and infectivity. Our data demonstrated that the loss of bb0164 resulted in a significant reduction in internalized Mn, increased sensitivity to oxidative stress, dysregulation of the BosR-RpoS virulence pathway, and a loss of infectivity in mice. The loss of bb0164 resulted in elevated rpoS, ospC, and dbpA expression and production, while bosR was not altered transcriptionally or post-transcriptionally. B. burgdorferi grown in chelated complete BSK-II media showed a similar sensitivity to oxidative stress and virulence dysregulation as the bb0164 mutant. These phenotypes were rescued by exogenous Mn and Zn without influencing the expression levels of bb0164 or bmtA. AlphaFold models of BB0164 were structurally divergent from the canonical bacterial Mn transporter, Bacillus subtilis MntH and B. burgdorferi BmtA, but shared high similarity with a calcium/cation antiporter superfamily member. Together, this study characterized BB0164 as a second non-canonical Mn transporter in B. burgdorferi that is essential for mammalian pathogenesis and likely supports metal homeostasis along with bmtA. More broadly, B. burgdorferi uses unique and uncharacterized mechanisms for metal homeostasis that supports physiology and pathogenesis of the spirochete during mammalian infection. Author SummaryLyme disease, caused by Borrelia burgdorferi, is the most common vector-borne illness in the United States and can result in a chronic inflammatory disease. B. burgdorferi acquires most of the necessary nutrients, including trace metals, from the host due to its limited metabolic capacity. B. burgdorferi has evolved a manganese-centric metabolism in place of the iron primarily used by other bacteria. Little is understood about manganese homeostasis in B. burgdorferi with a single transporter, BmtA, characterized to date. Here, we describe a second manganese transporter, encoded by bb0164, that is essential for infection, protects against oxidative stress, and alters genetic regulation. We found that BB0164, an annotated ion antiporter, does not structurally align with conserved manganese transporters from other bacteria. Interestingly, our work suggests bb0164 and bmtA are not subject to transcriptional regulation dependent on temperature or metal availability, differing from other bacterial manganese transporters. These findings indicate B. burgdorferi is uniquely using an antiporter protein for metal transport to support metal homeostasis, which further demonstrates the importance of manganese in borrelial pathogenesis.

microbiology↗

Quantifying PD1 saturation by PDL1 in tumor tissue using a novel RNA aptamer-based assay

BackgroundTherapeutic agents targeting the PD1-PDL1 interaction are of great clinical value, however accurately predicting which patients are most likely to benefit is challenging. Improved predictive biomarkers for anti-PD1 therapy are clearly needed. Quantifying PD1 saturation by PDL1 in tumor tissue has the potential to serve as such a biomarker. Here we report a novel bioassay called the PD1 Ligand Receptor Complex Aptamer (LIRECAP) assay and demonstrate it can be used to quantify the saturation of PD1 by PDL1 in formalin-fixed paraffin-embedded tumor biospecimens. ResultsThe PD1 LIRECAP assay was developed by identifying a pair of RNA aptamers. One aptamer preferentially binds to unoccupied PD1 (P aptamer) and the other to the PD1-PDL1 complex (C aptamer). P and C aptamers were added together to a formalin-fixed sample, and bound aptamer extracted. A 2-color qRT-PCR assay using a single set of primers was used to determine the ratio of the sample-bound C to P aptamers (C:P ratio) which reflected PD1 saturation by PDL1 in the sample. Quantification of PD1 saturation by PDL1 as determined by the PD1 LIRECAP assay correlated closely with PD1-mediated signaling and PD1-PDL1 proximity. Analysis of sarcoma FFPE biospecimens confirmed the assay is technically reproducible on clinical biospecimens. There were significant differences in PD1 saturation by PDL1 between patients as well as considerable intratumoral heterogeneity. ConclusionsThe PD1 LIRECAP assay is novel assay that can be used to quantify PD1 saturation by PDL1 in clinical biospecimens. The assay is technically feasible, reproducible, and has the potential to serve as a superior predictive biomarker for PD1/PDL1-based therapy. Similar assays based on this platform could be used in other systems and settings to quantify interaction between two molecules.

immunology↗